Clear The Air News Tobacco Blog Rotating Header Image

Quit Smoking

Study finds e-cigarettes caused one of the biggest drops in smoking rates

Where the government failed, the private sector succeeded.

http://economiccollapsenews.com/2016/06/27/study-finds-e-cigarettes-caused-one-of-the-biggest-drops-in-smoking-rates/

A new study suggests that e-cigarettes have helped cause one of the biggest drops in smoking rates ever recorded in Europe.

Published in the journal Addiction, more than six million Europeans have quit smoking and an additional nine million have reduced their cigarette consumption thanks to e-cigarettes.

Researchers say 48.5 million Europeans have tried an e-cigarette and 7.5 million are currently using the product. Of the millions using e-cigarettes, more than one-third (35.1 percent) have quit smoking and nearly one-third (32.2 percent) have slashed their smoking intake.

“These are probably the highest rates of smoking cessation and reduction ever observed in such a large population study,” said the study’s lead author, Dr. Konstantinos Farsalinos, in a statement. “The European Union data show that the use of electronic cigarettes seems to have a positive impact on public health for two main reasons: 1. High smoking cessation and reduction rates are observed, and 2. Electronic cigarette use is largely confined to smokers (current and former), with minimal use by non-smokers.”

Despite the positive results, governments everywhere are trying to either regulate it the same as tobacco cigarettes or prohibiting e-cigs from hitting the marketplace.

Perceptual and experiential factors in switching to e-cigarettes

World’s ugliest colour discovered

http://www.trtworld.com/life/worlds-ugliest-colour-discovered-127128

The world's "ugliest" color could help people quit smoking

The world’s “ugliest” color could help people quit smoking

Australian researchers looked for the most repulsive colour to help save lives.

A group of experts from a marketing company have released the results of a survey which found that Pantone 448c, also known as opaque couché, is the ugliest colour in the world.

Officially the world’s ugliest colour: Pantone 448 C (aka Opaque Couch) or as I like to call it Dark Green Brown.

The Australian Government had asked the research agency GfK Bluemoon to find the ugliest colour to use on cigarette boxes to encourage people to stop smoking.

Nearly a thousand smokers took part in the survey and chose the “drab, dark brown” colour, which they associated with “tar,” “dirty” and “death.”

After the survey Australia set out on December 1 to legislate that the colour must be used on plain packs of cigarettes alongside graphic health warnings.

The government hopes that the move will make people think twice about continuing the habit.

Australia was the first country to adopt plain packaging in 2012, and experienced a sharp fall in smoking immediately afterwards.

The United Kingdom, Ireland, and France followed suit, adopting similar “plain packaging” laws to effectively fight tobacco use.

On May 31, in honour of World No Tobacco Day, the World Health Organisation (WHO) tried to encourage other countries to adopt similar plain packaging for tobacco products, following Australia’s success.

The Guidelines for Implementation of Article 11 (Packaging and labelling of tobacco products) of the WHO Framework Convention on Tobacco Control (WHO FCTC) describes plain packaging as “measures to restrict or prohibit the use of logos, colours, brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style [plain packaging].”

WHO Director-General Dr Margaret Chan said on No Tobacco Day “Plain packaging reduces the attractiveness of tobacco products. It kills the glamour, which is appropriate for a product that kills people.”

“It restricts tobacco advertising and promotion. It limits misleading packaging and labelling. And it increases the effectiveness of health warnings.”

However, the result of the survey has been disputed.

Famous painter Leonardo Da Vinci used opaque couché to encolour the dress of the subject of his famous painting “Mona Lisa,” being inspired by popular clothing at that time in history.

So beauty is really in the eye of the beholder.

Interventions for tobacco use cessation in people living with HIV and AIDS

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011120.pub2/full

Abstract

Background

Tobacco use is highly prevalent amongst people living with HIV/AIDS (PLWHA) and has a substantial impact on morbidity and mortality.

Objectives

To assess the effectiveness of interventions to motivate and assist tobacco use cessation for people living with HIV/AIDS (PLWHA), and to evaluate the risks of any harms associated with those interventions.

Search methods

We searched the Cochrane Tobacco Addiction Group’s Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and PsycINFO in June 2015. We also searched EThOS, ProQuest, four clinical trial registries, reference lists of articles, and searched for conference abstracts using Web of Science and handsearched speciality conference databases.

Selection criteria

Controlled trials of behavioural or pharmacological interventions for tobacco cessation for PLWHA.

Data collection and analysis

Two review authors independently extracted all data using a standardised electronic data collection form. They extracted data on the nature of the intervention, participants, and proportion achieving abstinence and they contacted study authors to obtain missing information. We collected data on long-term (greater than or equal to six months) and short-term (less than six months) outcomes. Where appropriate, we performed meta-analysis and estimated the pooled effects using the Mantel-Haenszel fixed-effect method. Two authors independently assessed and reported the risk of bias according to prespecified criteria.

Main results

We identified 14 studies relevant to this review, of which we included 12 in a meta-analysis (n = 2087). All studies provided an intervention combining behavioural support and pharmacotherapy, and in most studies this was compared to a less intensive control, typically comprising a brief behavioural intervention plus pharmacotherapy.

There was moderate quality evidence from six studies for the long-term abstinence outcome, which showed no evidence of effect for more intense cessation interventions: (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.72 to 1.39) with no evidence of heterogeneity (I2 = 0%). The pooled long-term abstinence was 8% in both intervention and control conditions. There was very low quality evidence from 11 studies that more intense tobacco cessation interventions were effective in achieving short-term abstinence (RR 1.51, 95% CI 1.15 to 2.00); there was moderate heterogeneity (I2 = 42%). Abstinence in the control group at short-term follow-up was 8% (n = 67/848) and in the intervention group was 13% (n = 118/937). The effect of tailoring the intervention for PLWHA was unclear. We further investigated the effect of intensity of behavioural intervention via number of sessions and total duration of contact. We failed to detect evidence of a difference in effect according to either measure of intensity, although there were few studies in each subgroup. It was not possible to perform the planned analysis of adverse events or HIV outcomes since these were not reported in more than one study.

Authors’ conclusions

There is moderate quality evidence that combined tobacco cessation interventions provide similar outcomes to controls in PLWHA in the long-term. There is very low quality evidence that combined tobacco cessation interventions were effective in helping PLWHA achieve short-term abstinence. Despite this, tobacco cessation interventions should be offered to PLWHA, since even non-sustained periods of abstinence have proven benefits. Further large, well designed studies of cessation interventions for PLWHA are needed.

Plain language summary

Interventions to help people living with HIV and AIDS to stop using tobacco

Background: Tobacco use is common amongst people living with HIV and AIDS (PLWHA); it causes a range of health problems and accounts for many deaths. There is good evidence about interventions to help people quit tobacco use in the general population, however the effectiveness in PLWHA was not known.

Methods: We reviewed the available evidence from trials to help PLWHA stop using tobacco. This evidence is correct up to June 2015. We conducted analyses of whether people were able to successfully quit tobacco use in the long-term (six months and over) and short-term (measured at less than six months).

Results: We found 14 relevant studies including over 2000 participants. All studies, except one, were conducted in the United States (US). All studies compared a behavioural intervention with medication, to a control group. The behavioural intervention was delivered via a range of methods including face-to-face, telephones, computers, and text messages. Nicotine replacement therapy or varenicline (medications that help tobacco users quit) was also given. Control participants typically received a less intensive, brief behavioural intervention, and the same medication as the intervention group. Six studies of moderate quality evidence investigated long-term abstinence; they did not show clear evidence of benefit of the more intense intervention. Eleven studies of very low quality evidence investigated short-term abstinence. The evidence suggested that a more intense intervention combining behavioural support and medication might help people to quit in the short-term.

Quality of the evidence: The quality of the evidence was judged to be moderate for the long-term abstinence outcome and very low for the short-term abstinence outcome, and so further research is needed to increase our confidence in our findings.

World No Tobacco Day

Tobacco control cost-saving study dubbed ‘outstanding’

http://www.brunel.ac.uk/news-and-events/news/articles/Tobacco-control-cost-saving-study-dubbed-outstanding

Work to cash up potential health savings from stop smoking schemes has won a major European award.

EQUIPT, (European-study on Quantifying Utility of Investment in Protection from Tobacco) aims to calculate the costs and benefits of tobacco control across Europe.

The €2 million Brunel-led project has pocketed an Outstanding European Health Research Award from the European Network for Smoking and Tobacco Prevention.

EQUIPT will offer health providers and policy makers across Europe tailor-made figures on how much they can save from investing in tobacco control such as stop smoking schemes.

“In terms of saving lives through less smoking related diseases, this is very far reaching,” said study leader Dr Subhash Pokhrel. “It can also avoid different countries spending money on similar research.”

Big regional differences across Europe mean one size doesn’t fit all, when it comes to smoking statistics. Evidence strongly suggests hard-hitting, joined-up tobacco control programmes are the best way to stop people starting smoking and get more to stop. But regional European health providers and policy makers don’t have the tailored data to financially justify such prevention programmes.

EQUIPT uses comparative analysis to show European health providers how they can translate figures from similar English regions to predict tobacco control benefits locally.

Above helping regional health providers calculate value for money, “it should give us enough information to see if harmonising efforts on tobacco controls across Europe could be cost effective,” said Dr Pokhrel.

Led by Brunel’s Health Economics Research Group (HERG), EQUIPT is a partnership between Belgium, Croatia, Germany, Hungary, the Netherlands, Spain and the UK.

Editorial: Tobacco tax increases must be matched by more help for smokers

http://www.stuff.co.nz/dominion-post/80484061/Editorial-Tobacco-tax-increases-must-be-matched-by-more-help-for-smokers

OPINION: The Government stands accused of making a fortune out of tobacco addicts. The 10 per cent annual increase in tobacco taxes for the next four years will bring in a staggering $425m. The tax increases will, of course, hit the poor hardest.

NZ First leader Winston Peters raises the spectre of poor children going hungry while their addicted parents continue to buy cigarettes. Others have questioned whether the increase in taxes reduces tobacco consumption as much as the Government claims.

It has long been the conventional public health wisdom that price rises cut cigarette consumption. The Government says the 10 per cent annual tax rises in recent years have cut per capita consumption by around a quarter.

There is evidence, however, that the effect on consumption is weakening. Partly this is because the cigarette companies have not passed on the total tax increases, especially in the cheaper brands. If a 10 per cent tax increase leads to only a five per cent price increase, the effect on consumption is lower.

For that reason many public health experts called for a much stiffer tax increase, perhaps as high as 40 per cent in the first year and 20 per cent annual rises after that.

There is a risk that smokers simply factor in the 10 per cent rise and live with it. A much bigger increase would shock many more into quitting.

The Government would have been justified in doing this on public health grounds. After all, about 5000 people in New Zealand die prematurely each year as a result of smoking. Cutting smoking means saving lives.

But the same experts also called for much greater help for smokers to quit. The Government has not done this: it is happy to harvest another $425m from its tobacco tax and use it to help build a surplus (probably for future tax cuts).

The Government should have given a massive boost to quitlines and other programmes to help smokers stop. Poor tobacco addicts, who are disproportionately Maori or Pasifika, need much more help in quitting. Without that help, some will undoubtedly spend scarce family money on tobacco rather than food.

It is, after all, the poor who are the main target of the tax increases. Wealthy smokers won’t be affected, although wealthier people are much less likely to smoke. The middle classes are heading rapidly towards smoke-free status.

Quitlines make it easier for smokers to stop, although their success is modest because smoking addiction is so serious. The Government should be spending more and exploring more imaginative ways of helping addicts. Recent studies in the United States, for example, have explored the effects of simply paying people to quit.

Politicians like Winston Peters, on the other hand, need to be called to account. Is he saying the Government should scrap tobacco tax increases because they are “unfair”?

That would be a mistake.

Smoking, after all, wreaks havoc among poor families, killing and maiming productive family members. The war against smoking must continue.

100-day anti-smoking campaign in Beijing to encourage smokers to quit

http://www.newsx.com/world/30011-100-day-anti-smoking-campaign-in-beijing-to-encourage-smokers-to-quit

Beijing: China’s capital Beijing will launch a 100-day anti-smoking campaign from July 1 to encourage more smokers to quit.

The effort will build on the success already achieved since China’s strictest tobacco control regulation took effect in the capital last year, the China Daily reported on Friday.

Since then, tobacco control in Beijing has made significant progress, with smoking in indoor public places decreasing greatly, Mei Hongguang, deputy director for health promotion at the Beijing Municipal Commission of Health and Family Planning, said on Thursday.

During the campaign, launched jointly by the commission and the World Health Organisation, participants will be encouraged to receive professional services at clinics that help smokers quit at 16 major hospitals in Beijing, or they can seek advice and help through three health service hotlines, Mei said.

Smokers will be invited to interact and share their experiences on social media such as WeChat, he said.

Any resident in Beijing who is over 18 years old and has been smoking for more than a year is eligible to register until June 30, he said.

Participants who successfully quit smoking will have a chance to win prizes worth up to 20,000 yuan ($3,100), Mei said.

Since the start of controls last year, smoking in major public places, such as railways stations and hotels, has decreased, according to a survey conducted by the commission between March and April. The number of cigarettes sold in Beijing last year fell 2.71 percent from 2014, said Gao Xiaojun, the commission’s spokesman.

The survey, which looked at 5,100 residents and 728 businesses, found the greatest smoking decline in restaurants.

Only 6.7 percent of all facilities surveyed were found in violation of the regulation, compared with more than 23 percent a year ago when the regulation was adopted, Gao said.

More than 46 percent of smokers surveyed said they planned to quit, compared with 11.6 percent who said so before the regulation, Gao said.

Health law enforcement officers in Beijing had imposed penalties on more than 1,500 individuals and nearly 400 businesses as of the end of April, levying total fines of more than 1.12 million yuan.

E-cigarettes no longer considered medicinal products in Sweden

http://www.lexology.com/library/detail.aspx?g=9258ca21-ab20-4384-bcad-2a8d64044143

The Supreme Administrative Court has ruled that e-cigarettes not marketed for smoking cessation purposes should not be classified as medicinal products. This is contrary to the Medical Product Agency’s long-standing position and rulings of the first and second-instance courts. As a result, the EU Tobacco Product Directive (2014/40/EU) rules for e-cigarettes will apply to e-cigarettes in Sweden from May 20 2016, when the directive must be implemented in national legislation.

Facts

The Medical Product Agency had ordered a company to stop selling e-cigarettes with nicotine-containing liquids. The agency argued that the products had a high nicotine content, which is a pharmacologically active substance with an established medical use, primarily for smoking cessation.

The distributor argued that the e-cigarettes in question did not have a sufficiently strong pharmacological effect on the body’s functions to be classified as a medicinal product. Even if the e-cigarettes did have such an effect, they had no health benefits. The distributor claimed that it sold the e-cigarettes purely as a recreational product, with no claims that they were beneficial to health.

Both the first and second-instance courts dismissed the distributor’s arguments and held that e-cigarettes and nicotine-containing liquids should be classified as medicinal products. The appeal court stated that the manufacturers’ and distributors’ perceptions of the products’ use could not be considered decisive. The products were held to have scientifically documented pharmacological characteristics insofar as the active substance nicotine can be used to treat tobacco addiction, which results in nicotine cravings and withdrawal symptoms. This qualified as a beneficial health effect. The fact that the e-cigarettes were not used exclusively as medicinal products did not change this assessment and they were thus classified as medicinal products. The appeal court held that the Tobacco Product Directive does not prevent a member state from classifying e-cigarettes as medicinal products.

Decision

The Supreme Administrative Court held that all characteristics of a product must be considered when deciding on that product’s classification, including:
• the way it is used;
• how it is distributed;
• how well known it is among consumers; and
• the risks which may be involved with use.

It is not sufficient that a product has a pharmacological effect on the body’s functions. Referring to EU case law, the court stated that in order to be classified as a medicinal product, the product, if used as intended, must be capable of appreciably restoring, correcting or modifying physiological functions in human beings. The mere fact that the active substance affects the body’s functions is insufficient for it to be defined as a medicinal product.

The court did not consider that the Medical Product Agency’s scientific reports conclusively highlighted the effects that e-cigarettes had on smoking cessation and therefore did not demonstrate any e-cigarette health benefits (one of the prerequisites for medicinal product classification). Further, in its assessment of how e-cigarettes are distributed and used, the court referred to a report from the European Commission which showed that only 2% of Swedish respondents used e-cigarettes to stop smoking and that they did not consider the product to have any long-term effects on their smoking.

The court also noted that the e-cigarette distributor in this case had stated that the e-cigarettes were developed as a healthier, recreational alternative to normal tobacco cigarettes. They were designed to mimic traditional cigarettes and simulated cigarette smoke through their vapour. The addition of various aromas made product use pleasant. The products were not sold with any particular instructions on how the user should cut down on smoking or nicotine addiction.

The court therefore found that e-cigarettes were not medicinal products.

Comment

The Swedish market for e-cigarettes has until now been almost non-existent. However, this is likely to change following this decision. The judgment focused on the actual use of the products on the market and how they are marketed. Considering that no e-cigarettes are currently registered as medicinal products in Sweden, and that sales of non-registered e-cigarettes were virtually non-existent pending this decision, the Swedish respondents’ answers in the commission’s report to which the court referred should be reasonably affected. The court considered that because the way that these products are used and distributed will likely change following this decision, that classification of the product could also change.

The Supreme Administrative Court decision is something of a surprise in light of the lower-court decisions and agency case law. While the legislature in the ongoing implementation of the Tobacco Product Directive had mentioned that it would await the outcome of the judgment, it is likely that this particular outcome was not anticipated. This means that the directive’s rules for e-cigarettes will have to be put quickly into place in Swedish national law.

The judgment may also open up the possibility of introducing other smokeless nicotine products that would have been previously classified as medicinal products. It is uncertain whether the fact that e-cigarettes imitate tobacco cigarettes in terms of shape and vapour was decisive for the decision, and whether such anti-smoking products as lozenges or sprays could be considered general products. These questions remain unanswered.

For further information on this topic please contact Jonas Löfgren or Annie Kabala at Advokatfirman Lindahl KB by telephone (+46 8 527 70 800) or email (jonas.lofgren@lindahl.se or annie.kabala@lindahl.se). The Advokatfirman Lindahl KB website can be accessed at www.lindahl.se.

Swapping one vice for another? Ex-smokers who end up becoming ADDICTED to nicotine gum

• Under new legislation, cigarette packaging is to be stripped of its bright colours and will, in future, be a uniform green-brown colour
• To go by the experience of other countries, this will lead to many more smokers switching to nicotine replacement therapy (NRT) such as gum
• These effective products will inevitably see many become addicted to them

http://www.dailymail.co.uk/health/article-3605577/Ex-smokers-end-ADDICTED-nicotine-gum.html

My childhood was peppered with my father’s euphemisms for smoking. Every evening after our family meal, he’d get up from the table and inform us he was ‘just going to check on the weather’ — or ‘the oven’, or even ‘a giraffe’ he had apparently seen in the garden.

Each of these was actually an excuse for my dad to have his after-dinner cigarette. My father, Anthony, now 68, smoked more than 20 a day for 40 years — and this was a routine almost every night for the 20 years I lived at home.

But three years ago, he quit smoking. Instead of going out for a cigarette, he now fishes in his pocket for a packet of nicotine gum and pops a small, white square into his mouth, like a petit four.

Around an hour later, he will have another, then an hour after that we’ll hear the rustle of the packet again. For while he has given up cigarettes, he is now addicted to nicotine gum. He can’t go anywhere without it.

‘I never wanted to give up cigarettes,’ he says. ‘I enjoyed them too much. But the doctor said it was crazy to keep smoking. I thought about an e-cigarette, but I didn’t want to be one of those sad people outside buildings blowing apricot smoke over everyone, so I decided to use the gum.’

That was three years ago. Initially, the gum was prescribed by the NHS — you’re given a 12-week course (in fact, the manufacturer’s recommended dose), with the idea that you use it to wean yourself off nicotine.

But, like many people, Dad couldn’t do that. Instead, he started buying the gum in the High Street, where it is available everywhere, from Sainsbury’s to Boots. He buys a box, costing up to £26, a week and chews 15 gums a day (the maximum initial amount recommended by doctors before you should taper off and stop completely).

He says it works — ‘If I feel like a cigarette, I have a piece of gum and it stops the cravings’ — and has noticed real health benefits. ‘My breathing is already better and I can walk and run properly.’

But he is definitely addicted. ‘I take them everywhere with me. I can’t run out. One day, I’ll try to give up nicotine completely — but the gum is addictive.’ His case is far from unusual. While gum was meant to bridge the gap between addiction and freedom for smokers, many have trouble weaning themselves off it.

They now have a new addiction: to gum, with 10 per cent chewing it four times longer than they should (a year) and 5 per cent for two years. Some use it for ten years.

Under new legislation that came into effect last Friday, cigarette packaging is to be stripped of its bright colours and will, in future, be a uniform green-brown colour.

To go by the experience of other countries that have done this, it will lead to many more smokers switching to nicotine replacement therapy (NRT) products, such as gum.

And inevitably, many will end up addicted to it.

The nicotine in the gum is released on chewing and absorbed through the tissues lining the mouth.

When the taste becomes strong or hot (this signals that the nicotine has been released), users are told to ‘park’ the gum in the side of their cheek until the feeling fades, before continuing to chew.

There are two strengths, 2mg and 4mg. The latter (which Dad uses) is recommended for people on more than 20 cigarettes a day. One 2mg piece of gum has double the amount of nicotine absorbed (on average) from a cigarette, though experts say gum-chewers don’t absorb it all.

There is no doubt that gum, even a decade of use, is ‘safe’ compared with smoking.

Half of all lifelong smokers die early, losing around three months of life expectancy for every year after the age of 35 that they smoke, according to a report last month.

Some 8.7 million people in the UK still smoke.

As Professor John Britton, chairman of the Royal College of Physicians tobacco advisory group, explains, smokers are ‘like people in a nightclub when a fire breaks out’ — they just need a way out, and that’s what nicotine gum provides.

Yet while the gum doesn’t contain the toxins that put smokers at such high risk of disease and premature death, it may not be as benign as people think.

The leaflet that accompanies nicotine gum brand Nicorette, for instance, warns that ‘very common side-effects’ include stomach discomfort, nausea, headaches and tingling or numbness in hands and feet, with more than one user in ten affected. Less common are vomiting, palpitations and hives.

Some effects may be due simply to the act of chewing itself, as Dr Andy McEwen, of the National Centre for Smoking Cessation and Training, explains.

‘The effects of chewing ten to 15 pieces of gum a day are pretty onerous,’ he says. ‘That’s around one piece every hour, with recommended chewing of around 20 minutes, so people do say they have sore jaws. And nausea, dizziness, insomnia and headaches can also be side-effects of the gum, but they are for most medications.’

There is some evidence of more serious harm. In 2014, a study by scientists at the Virginia Bioinformatics Institute, in the U.S., found nicotine was such a powerful carcinogen, it caused thousands of cell mutations similar to those known to be a precursor to cancer.

But Professor Britton said while there was evidence that nicotine can promote cancer growth, it didn’t cause the disease.

‘The long-term risks have been tested as far as 12 years, and we know there were no very adverse health effects,’ he says — although he adds that the same cannot yet be said for 20-year or 30-year use. There may be a risk to unborn babies. A study by the Loma Linda University School of Medicine and California State University, in the U.S., found that, in rats, nicotine is absorbed by the foetus and can lead to high blood pressure and heart problems later in life (the NHS, however, says the gum is safe to use in pregnancy).

And patients who have recently had a stroke or heart attack, or have angina or heart rhythm problems, are advised to talk to their doctor before using the gum, because nicotine can increase heart rate and blood pressure.

People with dentures or dental work may also want to avoid gum because it can stick to them; prolonged use may irritate the mouth or affect the teeth.

But the fact remains that for the ‘small percentage’ using gum long-term, ‘nearly everything is safer than smoking’, says Dr McEwen.

There are more than 7,000 chemicals in cigarette smoke, including carbon monoxide, arsenic and cyanide, and at least 69 of them can cause cancer.

Most of the ingredients in nicotine gum, such as the gum base and flavourings, are the same as in normal chewing gum.

How addictive a nicotine product is depends on the speed of absorption, says Robert West, a professor of health psychology at University College London.

In theory, the nicotine in gum, which is absorbed relatively slowly into the bloodstream (taking around half an hour), shouldn’t be as addictive as people such as my father find it. So what’s going on?

‘Most people using the gum for years will have had failed attempts at giving up smoking,’ says Professor West. ‘They’ve made a mental calculation that they really don’t want to go back to smoking and are quite happy using the gum.

‘Most health professionals will tell you that you’d live a happier, richer, healthier life if you had no nicotine at all, but the gum is a buffer and a transition to abstinence.

Some people use it for many years — but most reduce their use eventually.’